Mohammad Jalali (aka, ‘MJ’) is a member of the faculty at Harvard Medical School and a senior scientist at MGH Institute for Technology Assessment. He was previously a research faculty at MIT Sloan School of Management and a consultant at the World Bank. MJ uses analytics and simulation-based approaches to help policymakers identify and develop high-leverage policies that not only are effective over the long haul, but also are not thwarted by unanticipated side effects. To achieve this goal, he spends a great deal of time working with decision-makers and policymakers, doing fieldwork and collecting different types of data that can inform richer models and analyses.

MJ’s work has been featured by national and international media outlets, including Associated Press, The Hill, Newsweek, Scientific American, Business Insider, and NPR. He is an associate editor of System Dynamics Review and is on the editorial board of the Journal on Policy and Complex Systems. He is the recipient of the 2015 Dana Meadows Award, the 2015 WINFORMS Excellence Award, and the 2014 Lupina Young Researcher Award. MJ received his PhD in Systems Engineering, with a concentration in management and health care systems, from Virginia Tech in 2015.

Latest News

New job opening

September 9, 2019
Two job opportunities (postdoc & research associate) are available to join my recently awarded opioid systems modeling project. See opportunities for more information. 

Grant application awarded by FDA

September 2, 2019
I’m pleased to share the great news that my grant application to develop a system dynamics model to inform opioid policies has been awarded by the FDA. So proud of my large and interdisciplinary team of amazing researchers from Harvard, MIT, Stanford, Michigan, Wash-St. Louis, Portland State, Northeastern, Homer Consulting, and Ventana Systems.

Grant application awarded by the EU

August 26, 2019
I’m so delighted to share the news that my first grant application (in my new job!) just got accepted by the European Union. This will be a large project (four-year collaboration with eight European countries) for data analysis and modeling to study the quality of life after cancer immunotherapy. The project will start in 2020.
<embed>
Copy and paste this code to your website.